相似文献
1
The Ebola epidemic crystallizes the potential of passive antibody therapy for infectious diseases.埃博拉疫情凸显了被动抗体疗法在治疗传染病方面的潜力。
PLoS Pathog. 2015 Apr 23;11(4):e1004717. doi: 10.1371/journal.ppat.1004717. eCollection 2015 Apr.
2
Ebola veteran promises an end to Congo's epidemic.埃博拉疫情“老兵”承诺终结刚果疫情。
Science. 2019 Aug 9;365(6453):526-527. doi: 10.1126/science.365.6453.526.
3
Infectious diseases. In Guinea, a long, difficult road to zero Ebola cases.传染病。在几内亚，实现埃博拉病例零新增的道路漫长而艰难。
Science. 2015 May 1;348(6234):485-6. doi: 10.1126/science.348.6234.485. Epub 2015 Apr 30.
4
Infectious disease: Mobilizing Ebola survivors to curb the epidemic.传染病：动员埃博拉幸存者遏制疫情。
Nature. 2014 Dec 18;516(7531):323-5. doi: 10.1038/516323a.
5
Ebola virus disease epidemic.埃博拉病毒病疫情
Workplace Health Saf. 2014 Nov;62(11):484. doi: 10.3928/21650799-20141014-02.
6
Preparing for the next Ebola epidemic.为下一次埃博拉疫情做准备。
Curr Biol. 2018 Jan 22;28(2):R51-R54. doi: 10.1016/j.cub.2018.01.011. Epub 2018 Jan 31.
7
The Ebola Epidemic. High hopes for Guinean vaccine trial.埃博拉疫情。几内亚疫苗试验寄予厚望。
Science. 2015 Jan 16;347(6219):219-20. doi: 10.1126/science.347.6219.219.
8
Design Improvements for Personal Protective Equipment Used in Ebola and Other Epidemic Outbreaks.用于埃博拉和其他传染病暴发的个人防护设备的设计改进。
Glob Health Sci Pract. 2017 Jun 27;5(2):325-328. doi: 10.9745/GHSP-D-17-00152.
9
Uganda gears up to contain Ebola epidemic as fears of spread cause panic.随着对埃博拉疫情蔓延的担忧引发恐慌，乌干达准备好控制疫情。
BMJ. 2012 Aug 1;345:e5210. doi: 10.1136/bmj.e5210.
10
Critical Choices for the WHO After the Ebola Epidemic.埃博拉疫情后世界卫生组织面临的关键抉择
JAMA. 2015 Jul 14;314(2):113-4. doi: 10.1001/jama.2015.6940.
引用本文的文献
1
Diverse Effects of Exosomes on COVID-19: A Perspective of Progress From Transmission to Therapeutic Developments.外泌体对 COVID-19 的多种影响：从传播到治疗发展的进展视角。
Front Immunol. 2021 Jul 28;12:716407. doi: 10.3389/fimmu.2021.716407. eCollection 2021.
2
Unleashing the potential of cell membrane-based nanoparticles for COVID-19 treatment and vaccination.释放基于细胞膜的纳米粒子在 COVID-19 治疗和疫苗接种方面的潜力。
Expert Opin Drug Deliv. 2021 Oct;18(10):1395-1414. doi: 10.1080/17425247.2021.1922387. Epub 2021 Jun 6.
3
Quantum leap of monoclonal antibody (mAb) discovery and development in the COVID-19 era.新冠疫情时代下单克隆抗体（mAb）发现和开发的量子飞跃。
Semin Immunol. 2020 Aug;50:101427. doi: 10.1016/j.smim.2020.101427. Epub 2020 Nov 17.
4
SARS-CoV-2/COVID-19 and advances in developing potential therapeutics and vaccines to counter this emerging pandemic.严重急性呼吸综合征冠状病毒 2（SARS-CoV-2）/COVID-19 及其相关疗法和疫苗的研究进展，以应对这一新兴的大流行病。
Ann Clin Microbiol Antimicrob. 2020 Sep 2;19(1):40. doi: 10.1186/s12941-020-00384-w.
5
Advances and challenges in the prevention and treatment of COVID-19.COVID-19 的预防和治疗的进展与挑战。
Int J Med Sci. 2020 Jul 9;17(12):1803-1810. doi: 10.7150/ijms.47836. eCollection 2020.
6
Repositioning chloroquine as antiviral prophylaxis against COVID-19: potential and challenges.将氯喹重新定位为预防 COVID-19 的抗病毒药物：潜力与挑战。
Drug Discov Today. 2020 Oct;25(10):1786-1792. doi: 10.1016/j.drudis.2020.06.030. Epub 2020 Jul 3.
7
Emergence of novel coronavirus and progress toward treatment and vaccine.新型冠状病毒的出现以及治疗和疫苗的研发进展。
Rev Med Virol. 2020 Jul;30(4):e2116. doi: 10.1002/rmv.2116. Epub 2020 Jun 4.
8
Understanding novel COVID-19: Its impact on organ failure and risk assessment for diabetic and cancer patients.了解新型冠状病毒肺炎：其对器官衰竭的影响及对糖尿病和癌症患者的风险评估。
Cytokine Growth Factor Rev. 2020 Jun;53:43-52. doi: 10.1016/j.cytogfr.2020.05.001. Epub 2020 May 6.
9
Initial success in the identification and management of the coronavirus disease 2019 (COVID-19) indicates human-to-human transmission in Wuhan, China.新冠病毒病（COVID-19）的鉴定和管理方面最初取得的成功表明，在中国武汉存在人与人之间的传播。
Int J Biol Sci. 2020 Apr 6;16(11):1846-1860. doi: 10.7150/ijbs.45018. eCollection 2020.
10
Therapeutic strategies in an outbreak scenario to treat the novel coronavirus originating in Wuhan, China.针对源自中国武汉的新型冠状病毒在疫情爆发情况下的治疗策略。
F1000Res. 2020 Jan 31;9:72. doi: 10.12688/f1000research.22211.2. eCollection 2020.
本文引用的文献
1
Recognition determinants of broadly neutralizing human antibodies against dengue viruses.广谱中和人抗登革病毒抗体的识别决定因素。
Nature. 2015 Apr 2;520(7545):109-13. doi: 10.1038/nature14130. Epub 2015 Jan 12.
2
Ebola raises profile of blood-based therapy.埃博拉提升了基于血液疗法的关注度。
Nature. 2015 Jan 1;517(7532):9-10. doi: 10.1038/517009a.
3
Update: ebola virus disease epidemic - West Africa, December 2014.更新：2014年12月西非埃博拉病毒病疫情
MMWR Morb Mortal Wkly Rep. 2014 Dec 19;63(50):1199-201.
4
Plant-based vaccines against viruses.基于植物的病毒疫苗。
Virol J. 2014 Dec 3;11:205. doi: 10.1186/s12985-014-0205-0.
5
Hyperimmune serum from healthy vaccinated individuals for Ebola virus disease?来自接种过埃博拉病毒病疫苗的健康个体的超免疫血清？
Lancet Glob Health. 2014 Dec;2(12):e686. doi: 10.1016/S2214-109X(14)70341-9. Epub 2014 Oct 30.
6
Broadly neutralizing anti-HIV-1 antibodies require Fc effector functions for in vivo activity.广谱中和抗 HIV-1 抗体需要 Fc 效应功能才能在体内发挥作用。
Cell. 2014 Sep 11;158(6):1243-1253. doi: 10.1016/j.cell.2014.08.023.
7
A practical treatment for patients with Ebola virus disease.埃博拉病毒病患者的一种实用治疗方法。
J Infect Dis. 2015 Feb 15;211(4):661-2. doi: 10.1093/infdis/jiu474. Epub 2014 Aug 25.
8
Polyfunctional Fc-effector profiles mediated by IgG subclass selection distinguish RV144 and VAX003 vaccines.多效性 Fc 效应子谱由 IgG 亚类选择介导，可区分 RV144 和 VAX003 疫苗。
Sci Transl Med. 2014 Mar 19;6(228):228ra38. doi: 10.1126/scitranslmed.3007736.
9
Profile and persistence of the virus-specific neutralizing humoral immune response in human survivors of Sudan ebolavirus (Gulu).苏丹埃博拉病毒（Gulu）感染者体内病毒特异性中和性体液免疫应答的特征和持久性。
J Infect Dis. 2013 Jul 15;208(2):299-309. doi: 10.1093/infdis/jit162. Epub 2013 Apr 12.
10
Which are the antibodies to watch in 2013?2013 年需要关注哪些抗体？
MAbs. 2013 Jan-Feb;5(1):1-4. doi: 10.4161/mabs.22976. Epub 2012 Dec 19.
Zotero 插件